Form 4: VolitionRx CEO Cameron Reynolds Receives Stock Award in Lieu of Cash Compensation

Cameron John Reynolds, CEO of VolitionRx Ltd, was granted 103,243 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

Summary

• On September 1, 2024, Cameron John Reynolds, the President and CEO of VolitionRx Ltd, received 103,243 restricted stock units (RSUs) under the company's 2015 Stock Incentive Plan.
• These RSUs were awarded in place of cash compensation.
• The RSUs vest in three installments of 34,415 units, 34,414 units, and 34,414 units on September 1, 2024, October 1, 2024 and November 1, 2024, respectively.
• The RSUs are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date.
• Upon vesting and settlement, Reynolds will receive shares of common stock equal to the number of RSUs that have vested.
• Reynolds directly owns 1,977,593 shares of VolitionRx common stock.
• He also indirectly owns 1,007,718 shares through Concord International, Inc., where he is the majority shareholder, and 34,076 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not inherently convey positive or negative sentiment. It simply reports a transaction.

Positives

• The award of RSUs aligns the CEO's interests with those of the shareholders, as the value of the RSUs is tied to the company's stock performance.
• The vesting schedule incentivizes the CEO to remain with the company for the long term.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders (such as officers and directors) have transactions involving the company's securities. It provides transparency to the market regarding insider activity.

Comparison to Industry Standards

• Stock awards are a common form of executive compensation in the biotechnology industry, often used to align management's interests with those of shareholders.
• The vesting schedule is typical for RSU grants, incentivizing long-term performance and retention.
• The size of the grant would need to be compared to similar companies and executive roles to determine if it is in line with industry standards.

Stakeholder Impact

• The RSU grant could be viewed positively by shareholders as it aligns management's interests with theirs.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates